

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

December 12, 2024

To The Manager, Listing Department National Stock Exchange of India Ltd. Plot No. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai -400 051 Symbol: CONCORDBIO	To General Manager, Listing Department BSE Limited Phiroze Jeejabhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 543960
---	---

Dear Sir/Ma'am,

Sub: Intimation in terms of the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (“SEBI LODR Regulations”) on behalf of Concord Biotech Limited (“Company”)

Pursuant to provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that M/s. Concord biotech Limited has made investment of USD 1,000,000 in Compulsorily convertible Notes of M/s. Palvella Therapeutics, Inc

In terms of the above referred provisions of the SEBI LODR Regulations, read with circular dated November 11, 2024 issued by the Securities and Exchange Board of India, bearing ref. no. SEBI/HO/CFD/PoD2/CIR/P/0155 (“said SEBI Circular”).

The requisite details of terms of the provisions of Regulation 30 read with Schedule III of the SEBI LODR Regulations and the said SEBI circular, are included in Annexure A, as enclosed herewith.

This is for your information and records.

For, Concord Biotech Limited

Prakash Sajnani
Company Secretary and Compliance Officer
M. No. F6242

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.
Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440
Email ID: complianceofficer@concordbiotech.com

Annexure-A

Sr. No.	Particulars	Details
a)	Name of the target entity, details in brief such as size, turnover etc.	<p>Palvella Therapeutics, Inc. (referred as "Palvella") Incorporated under General Corporation Law of the State of Delaware</p> <p>Authorised Share Capital (as on December 31, 2023): Shares of 20655895 at per share USD 0.00001</p> <p>Issued share capital of 15,360,787 at per share value of USD 0.00001</p> <p>Net-worth (as on March 31, 2023): USD 7,06,03,000</p> <p>(Palvella is following Calendar Year)</p>
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at arm's length	<p>The acquisition does not fall within the purview of related party transaction(s).</p> <p>None of the promoter/ promoter group/ group companies have any interest in the Palvella.</p>
c)	Industry to which the entity being acquired belongs	Biopharmaceutical Industry
d)	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	To establish a partnership for the manufacture and commercialization of Qtorin™ utilized in the treatment of serious, rare genetic skin diseases, this funding will strengthen our collaboration with Palvella through a financial commitment, enhancing the potential for exporting our products to them.
e)	brief details of any governmental or regulatory approvals required for the acquisition;	Automatic route
f)	indicative time period for completion of the acquisition	The equity shares against the current investment will be allotted within 90 days from the Investment.
g)	consideration - whether cash consideration or share swap or	Cash Consideration

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

	any other form and details of the same;											
h)	cost of acquisition and/or the price at which the shares are acquired;	Investment for an amount of USD 1,000,000 in Compulsorily Convertible Notes which shall be converted in around 71,446 Equity Shares										
i)	percentage of shareholding / control acquired and / or number of shares acquired;	Not Applicable										
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>Palvella Therapeutics is in business of clinical trial for Developing and Commercializing Treatments for Rare Genetic Skin Diseases.</p> <p>Brief Details of Palvella are as under:</p> <table border="1"><thead><tr><th>Particulars</th><th>Details</th></tr></thead><tbody><tr><td>Registration number</td><td>20224295364</td></tr><tr><td>Date of Incorporation</td><td>May 30,2018</td></tr><tr><td>History of last 3 years' Turnover</td><td>Year 2023: Nil Year 2022: Nil Year 2021: Nil (Company is following calendar year)</td></tr><tr><td>Country of Presence</td><td>United states of America</td></tr></tbody></table>	Particulars	Details	Registration number	20224295364	Date of Incorporation	May 30,2018	History of last 3 years' Turnover	Year 2023: Nil Year 2022: Nil Year 2021: Nil (Company is following calendar year)	Country of Presence	United states of America
Particulars	Details											
Registration number	20224295364											
Date of Incorporation	May 30,2018											
History of last 3 years' Turnover	Year 2023: Nil Year 2022: Nil Year 2021: Nil (Company is following calendar year)											
Country of Presence	United states of America											